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AbstrAct
Introduction Saphenous vein grafts (SVGs) remain 
the most often used conduits in coronary artery bypass 
grafting (CABG). However, they are prone to vein graft 
disease (VGD) during follow-up, which may compromise 
clinical outcomes. Injury to the SVG endothelium during 
harvesting and storage promotes neointimal hyperplasia 
that can advance to atherosclerosis characterised by 
SVG failure. This trial investigates the potential benefit 
of DuraGraft, a novel, one-time intraoperative graft 
treatment developed to efficiently protect the structural 
and functional integrity of the vascular endothelium, 
on the development and progression of VGD in CABG 
patients.
Methods and analysis This ongoing prospective 
randomised, double-blinded multicentre trial 
(NCT02272582/NCT02774824) includes patients 
undergoing isolated CABG requiring at least two 
SVGs. It compares the impact of DuraGraft, a novel 
treatment against VGD versus the standard-of-care 
(SOC; heparinised saline) using a within-patient 
randomisation (with one SVG treated with DuraGraft 
and the other treated with SOC). Besides clinical 
assessments, patients undergo longitudinal 64-slice or 
better multidetector CT (MDCT) angiography of paired 
grafts (within each patient) at 4–6 weeks, 3 months and 
12 months. Primary endpoints will be the magnitude 
of change in mean wall thickness and lumen diameter 
(stenosis) of paired grafts, at 3 and 12 months, 
respectively. Besides the evaluation of overall safety, 
longitudinal assessment of each graft (secondary 
endpoint) is performed in order to obtain insight into 
graft behaviour after CABG. Enrolment of 119 patients 
was successfully completed, and analysis of MDCT 
angiography follow-up is ongoing with the completed 
analysis becoming available by end of first quarter of 
2018.
Ethics and dissemination The regional ethics 
committees have approved the trial. Results will be 
submitted for publication.
Clinical trial identifier NCT02272582 and 
NCT02774824.
IntroduCtIon
Coronary artery bypass grafting (CABG) is 
the standard of care for multivessel coro-
nary disease.1 2 However, saphenous vein 
graft (SVG) patency loss due to vein graft 
Key questions
What is already known about this subject?
 ► Saphenous vein grafts (SVGs) are the most often 
used conduits for coronary artery bypass grafting 
(CABG). However, their use is hampered by loss of 
graft patency over time due to vein graft disease 
(VGD) resulting in graft failure potentially impairing 
long-term clinical outcomes.
 ► Damage to the conduit’s endothelium during 
harvest and storage (prior to anastomosis) has 
been identified as the main trigger for VGD. 
Importantly, standard intraoperative solutions (ie, 
saline or ex vivo blood) are not able to sufficiently 
protect the conduit’s endothelium thereby 
promoting failure and poor long-term patency.
What does this study add?
 ► This trial will establish whether pretreatment 
of SVGs with DuraGraft, an endothelial damage 
inhibitor, has the potential to mitigate negative 
remodelling by reducing intima hyperplasia (early 
signs of VGD) and graft lumen loss (late signs) in 
CABG patients.
 ► It will further provide important insight into the 
longitudinal remodelling behaviour and (patho-)
physiology of SVGs post-CABG.
How might this impact on clinical practice?
 ► Novel graft treatments specifically designed to 
protect the structural and functional integrity of the 
conduit’s endothelium may substantially reduce the 
occurrence of VGD thereby further improving long-
term outcomes after CABG.
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disease (VGD) and consecutive vein graft failure (VGF) 
remains a major problem resulting in impaired clinical 
long-term outcomes.3 VGF rates have been reported 
to range from 15% to 29%,4 while about 50% of SVGs 
fail by 10 years post-CABG.3 5 6 Long-term graft patency 
itself is determined by multiple important factors, such 
as the progress of the patient’s coronary artery disease, 
quality of target vessel, quality of anastomosis, bypass 
run-off and, most importantly, the quality of the graft 
itself. Several aspects play a crucial role in preserving 
the SVG’s quality: (1) harvesting techniques to minimise 
trauma; (2) the impact of hydrostatic pressure during 
intraoperative distensions when checking for potential 
leakages and (3) sufficient intraoperative graft storage 
between harvesting and reperfusion after completion of 
anastomosis in order to protect the SVG endothelium 
in its structure and function.3 7–9 In fact, endothelial 
injury of the endothelial layer promotes leucocyte and 
platelet adhesion leading to chronic inflammation and 
an obliterative lesion, which may result in SVG stenosis 
and finally occlusion.10 A number of ex vivo investiga-
tions have highlighted the importance of intraoperative 
preservation of the SVG’s endothelium to reduce the 
problem of VGF.11–15 More recently, a substudy of the 
PREVENT-IV trial further demonstrated that neither 
saline nor autologous blood (although being the most 
commonly used solutions) are capable to sufficiently 
preserve the SVG endothelium in regard to its structure 
and function during ischaemic storage.6 Hence, there is 
a clinical need for improved intraoperative SVG preser-
vation strategies.
In this context, DuraGraft is one of the most widely 
recognised solutions for the intraoperative treatment 
and preservation of the SVG’s endothelium during isch-
aemic storage. DuraGraft is based on a physiological salt 
solution and further contains glutathione and L-ascorbic 
acid, antioxidants and arginine, a substrate for nitric 
oxide synthase in endothelial cells to systematically 
protect the endothelium against ischaemic injury during 
storage. In several ex vivo studies, Thatte and colleagues 
evaluated the effect of DuraGraft against other solutions 
(ie, saline or blood based solutions) used for storage of 
SVGs.11 16 When using multiphoton imaging to elucidate 
the metabolic changes that take place during intraop-
erative storage of SVGs, the authors demonstrated that 
DuraGraft outperformed other solutions such as saline 
or blood, and it was capable of protecting endothelial 
structure and function for up to 24 hours of storage.11 
However, to date, despite these encouraging ex vivo data, 
systematic data validating the clinical efficacy of Dura-
Graft to prevent SVGs from the development of intimal 
hyperplasia leading to VGD and subsequent VGF is still 
pending.
This trial aims to investigate the potential benefit of 
DuraGraft, a novel, one-time intraoperative graft treat-
ment developed to efficiently protect the structural and 
functional integrity of the vascular endothelium on the 
development and progression of VGD and failure in 
CABG patients using longitudinal multidetector CT 
(MDCT) angiography.
MEtHods and analysIs
trial design
The trial is designed as a prospective, multicentre, 
randomised, double-blinded, comparative within-patient 
study to evaluate the use of DuraGraft, a one-time, intra-
operative graft treatment, versus heparin dosed saline 
(standard of care) in patients for up to 12 months after 
undergoing isolated CABG.
trial registration
The trial is registered at  Clinicaltrials. gov under the iden-
tifiers: NCT02272582 and NCT02774824.
objectives
Primary objectives
The primary short-term objective is to compare the impact 
of DuraGraft, a novel, one-time intraoperative graft treat-
ment to protect the structural and functional integrity 
of the vascular endothelium against the standard of care 
by evaluating the magnitude of change in the mean wall 
thickness of paired grafts within patients at 4–6 weeks 
and at 3 months following CABG surgery using 64-slice 
or better MDCT angiography. The primary long-term 
objective is to further compare the effect of DuraGraft 
against the standard of care by evaluating the effect on 
graft patency, more precisely by assessing the magnitude 
of change in a weighted average of mean lumen diam-
eter and lumen diameter at maximum stenosis of paired 
grafts at 12 months following CABG surgery using 64-slice 
or better MDCT angiography.
Secondary objectives
The secondary objectives aim:
 ► to evaluate the safety of DuraGraft over the 12-month 
postsurgery period
 ► to assess composite incidences of major adverse 
cardiac events (MACEs) (death, myocardial infarc-
tion (MI) and repeat revascularisation), angina, ar-
rhythmias and shortness of breath (SOB) over the 
12-month postsurgery period.
Patient population
Eligible patients include those aged between 18 and 
80 years undergoing primary and isolated, multivessel 
CABG requiring at least two SVGs. Patients with previous 
heart surgery, poor left ventricular ejection fraction, 
other significant valve disease, need for aortic aneurysm 
repair, with a stroke or transient ischaemic attack within 
the previous 12 weeks or any contraindication to cardio-
pulmonary bypass are excluded. Please see box 1 for full 
list of all inclusion and exclusion criteria.
In addition, numerous preoperative demographics 
and characteristics as well as intraoperative parameters 
and SVG characteristics were recorded (please see online 
supplementary information for further details).
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Patient screening
All patients undergo a screening assessment before enrol-
ment including:
1. review of all inclusion and exclusion criteria to 
determine eligibility
2. documentation of the medical history including prior 
medications
3. documentation of demographic information
4. conduct of a 12-lead ECG.
A screening log is maintained at each investigational 
site to record those patients who are screened but not 
enrolled and to capture the reason why patients were not 
enrolled.
randomisation
A randomisation schedule was developed to ensure 
appropriate randomisation allocation of the SVG being 
grafted to the targeted regions. A dedicated block rando-
misation schedule was also developed to ensure that at 
least four African-American patients and four Hispanic 
patients are enrolled. Patients are randomised using a 
balanced simple random sample allocation scheme. The 
randomisation assignments are as follows:
 ► DuraGraft left proximal (A) – saline right distal (B)
 ► DuraGraft left distal (A) – saline right proximal (B)
 ► DuraGraft right proximal (B) – saline left distal (A)
 ► DuraGraft right distal (B) – saline left proximal (A).
Each randomised patient receives two SVGs, alter-
nating target region A (circumflex or diagonal or other) 
and target region B (right coronary system or diagonal or 
other) and alternating (proximal vs distal) segments of 
the harvested SVG.
Blinding
Only the personnel who manages the randomisa-
tion and allocation schedule will remain unblinded. 
The surgeon, other staff in the operating room and 
the personnel collecting the intraoperative data are 
completely blinded to the preservation and storage 
solutions used for the two SVGs in each enrolled 
patient. Since DuraGraft is a transparent solution, it is 
completely indistinguishable from the standard of care 
(heparinised saline). The cardiologists assessing clinical 
events and the radiologists reading the MDCT angiog-
raphies are also blinded to the solutions that have been 
used to preserve and store the SVGs intraoperatively.
Follow-up
All patients will have a follow-up by a clinic visit at 4–6 
weeks, 3 months and at 12 months after CABG (see 
table 1 and 2). Each visit will include documentation of 
concomitant medication information, adverse events, 
glomerular filtration rate (GFR) and the conduction of 
an ECG and an MDCT angiography. If a patient with-
draws prior to completion of the study, the reason for 
this decision will be recorded in the case report form 
(CRF). Whenever possible, all end-of-study procedures 
box 1 Inclusion and exclusion criteria
Inclusion criteria
Patients will be eligible for inclusion in the study if they meet ALL of 
the following criteria:
 ► Patient is to undergo primary, multivessel coronary artery bypass 
grafting (CABG) with at least two saphenous vein graft (SVGs).
 ► Patient is >18 years and <75 years of age.
 ► Patient has no contraindications to cardiopulmonary bypass.
 ► Patient is willing and able to provide consent and shows 
commitment to participate in a follow-up evaluation, including a 
clinical visit between 4–6 weeks and 3 months post-CABG.
 ► If female, patient is surgically sterile or postmenopausal.
 ► Patient has not had previous CABG surgery.
 ► Patient is hemodynamically stable.
Exclusion criteria
Patients will be excluded from the study if ANY of the following 
conditions are present:
 ► in situ internal mammary artery (IMA) graft(s) only (no SVG or free 
arterial grafts)
 ► prior CABG or planned concomitant valve surgery or aortic 
aneurysm repair
 ► pregnant or lactating woman
 ► left ventricular ejection fraction <40%
 ► known to be HIV positive, is receiving antiretroviral drugs or is 
immunosuppressed
 ► patient has an acute infection at screening
 ► active chronic bacterial, parasitic or viral infection within 3 months 
prior to CABG surgery
 ► malignancy diagnosed within the previous 5 years (except 
successfully resected basal cell cancer)
 ► unable to provide consent or undergoing emergency cardiac 
surgery for an immediately life-threatening condition
 ► participating in a device study or received active drug product in 
an investigational drug study within 3 months prior to screening
 ► patient has a history of transient ischaemic attack or stroke within 
the 12 weeks prior to the CABG procedure
 ► significant renal impairment (glomerular filtration 
rate (GFR) <50 mL/min)
 ► patient has liver impairment as demonstrated by hepatic 
transaminases (AST and/or ALT) >2.5 × upper limit of normal 
(ULN) or conjugated bilirubin >1.5 × ULN
 ► any condition or disease detected prior to study start that 
would render the patient unsuitable for the study place the 
patient at undue risk or interfere with the ability of the patient 
to complete the study in the opinion of the investigator (eg, drug 
dependence and mental illness)
 ► uncontrolled diabetes mellitus (HbA1C >10%)
 ► confirmed significant allergic reactions against any drug or 
multiple allergies (non-active hay fever is acceptable)
 ► uninterrupted use of systemic steroids or immunosuppressive 
agents
 ► platelet count <100 000/mm3, haematocrit >62% (Hb >18 g/dL) or 
<30% (Hb <10 g/L)
 ► varicose veins or veins <2 mm diameter
 ► target coronary artery <1.5 mm in internal diameter
 ► diffuse coronary disease
 ► severe uncontrolled systemic hypertension (ie, systolic pressure 
>160 mm Hg)
 ► prior severe reaction to contrast dye.
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will be conducted on all patients who withdraw or who 
are discontinued from the study.
Ethics and informed consent
All patients provided written informed consent before 
enrolment into the trial.
Preservation solution
DuraGraft (SOMVC001) is a specifically designed 
one-time intraoperative treatment to protect against 
damage to the structure and function of the vascular 
endothelium (figure 1). DuraGraft is formulated into 
an ionically and pH-balanced physiological salt solution 
containing glutathione, L-ascorbic acid, and L-arginine 
and other protective ingredients that protect the conduit 
from the damaging effects of ischaemia (during storage) 
and handling during CABG.
Conduit harvesting and intraoperative treatment with 
duraGraft
Routinely, all patients will undergo a preoperative evalu-
ation of SVG diameters (luminal diameter) using ultra-
sound assessment as well as clinical evaluation by the 
surgeon. Those SVGs that appear to be very atheroscle-
rotic or which have a luminal diameter less than 2 mm 
will be excluded prior to surgery. The SVG is harvested 
using state-of-the-art harvesting (either open or endo-
scopic) and optimal handling techniques (ie, atraumatic 
surgical technique, avoidance of over pressurisation 
during checking for leakage, excessive handling and 
distortion) in order to reduce traumatic damage to the 
conduit’s endothelium. The SVG segment will be divided 
into two smaller segments that are used for grafting to the 
two different target regions (A and B). Each segment will 
be carefully flushed with and stored within the assigned 
solution. Storage time from storage to anastomosis is 
recorded for each of the conduits with a recommended 
duration of at least 15 min. The SVG segments are only 
exposed to the assigned preservation solution from the 
time of harvest until completion of distal and proximal 
anastomosis and reperfusion.
CaBG procedure
CABG surgery either using on-pump or off-pump tech-
niques (at the discretion of the surgeon) is carried out 
according to standard and state-of-the-art surgical techniques 
as described elsewhere. Flow measurements are performed 
for each conduit and recorded using a hand-held flow 
metre after reperfusion and prior to chest closure.
MdCt angiography protocol
The protocol used in this trial for the assessment of wall 
thickness is based on a validated method by Lau et al,17 
while for the evaluation of significant stenosis and/or 
graft occlusion, the Fitzgibbon’s scale B and O is used. 
MDCT examination is performed with a 64-slice or better 
scanner (Lightspeed Plus, GE Medical Systems) for angi-
ographic evaluation of grafts as follow-up procedure at 
4–6 weeks, 3 months and 12 months (please see online 
supplementary information for further technical details).
data collection
All study information, surgical procedural details, postop-
erative details, concomitant medications and serious and 
non-serious adverse events will be collected in the Elec-
tronic Data Capture (EDC) system. Site personnel will 
perform data entry and data corrections in the electronic 
case report form (eCRF).
Quality control and data validation procedures will be 
applied to ensure the validity and accuracy of the clinical 
database.
Primary and secondary endpoints and safety parameters
The primary short-term endpoint is the magnitude of 
change between 4–6 weeks and 3 months post-CABG 
surgery in mean wall thickness between the paired 
grafts as determined by 64-slice or better MDCT angi-
ography. The wall thickness will be calculated every 
10 mm for all grafts (varying lengths of the grafts and 
thus number of measurements used in creating the 
average for each graft) by subtracting the lumen diam-
eter in millimetre using contrast enhanced CT from 
the total vessel diameter in millimetre using non-en-
hanced CT and dividing by two. Each 10 mm segment 
is graded for quality, and the mean wall thickness for 
the whole graft will be computed as the average of all 
wall thickness measures of acceptable quality for each 
Figure 1 DuraGraft treatment solution.
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of the study grafts at 4–6 weeks and 3 months. The 
magnitude of change will be calculated per graft as 
the difference between the 4–6 weeks and the 3-month 
time points. The magnitude of these changes will then 
be compared between the paired grafts. The primary 
long-term endpoint will be the change from 4–6 weeks 
to 12 months following CABG surgery in lumen diam-
eter calculated as the average of the mean lumen diam-
eter over each graft and the lumen diameter at point of 
maximal stenosis within graft, using 64-slice or better 
MDCT angiography (figures 2 and 3).
The secondary efficacy endpoints will assess addi-
tional parameters for wall thickness, total lumen diam-
eter, maximum degree of stenosis and others in a 
paired fashion (DuraGraft-treated SVG vs saline-treated 
SVG) and also in a longitudinal fashion analysing 
changes from 4 weeks to 6 weeks and 3 months to 12 
months for each graft.
The primary safety endpoint is the incidence of vein 
graft thrombosis (occlusion). The secondary safety 
endpoints are (1) incidence of composite safety endpoints 
consisting of MACE (death, MI and repeat revascularisa-
tion), increased angina, arrhythmias, SOB, graft occlu-
sion and significant stenosis based on Fitzgibbon’s scale B 
and O, if determined to be related to specific graft, and 
(2) incidence of adverse events.
Primary safety endpoints as well as all composite safety 
endpoints will be adjudicated by an independent blinded 
review committee to determine if the adverse cardiac 
events can be attributed to a graft level event.
statistical considerations and analysis
Statistical analyses will be performed using SAS V.9.4 or 
higher. Unless otherwise specified, all statistical tests will 
be two sided and performed at a significance level of 0.05. 
No adjustments for multiple testing will be done. Study 
Figure 2 MDCT analysis protocol: each graft was evaluated from proximal to distal in 10 mm intervals. LD, lumen diameter; 
MDCT, multidetector CT; TVD, total vessel diameter; WT, wall thickness.
Figure 3 Exemplary primary short-term and long-term endpoint MDCT angiography calculation. LD, lumen diameter; MDCT, 
multidetector CT; TVD, total vessel diameter; WT, wall thickness.
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variables will be summarised using descriptive statistics. 
These will include N, mean, median, SD, first (Q1) and 
third (Q3) quartiles and minimum and maximum for 
continuous variables. Number of subjects and propor-
tions will be used to summarise categorical variables. 
Prior to any parametric analyses, basic assumptions of 
the variable being tested will be checked, and if they are 
violated, data transformations, non-parametric analyses 
or other appropriate methods will be performed (such 
as Wilcoxon signed-rank test). For purposes of data inter-
pretability, the average change score, by treatment group, 
will be presented, along with the average change in the 
parameter of interest between the paired grafts.
Efficacy analysis
Primary and secondary endpoint analysis
The primary endpoint analysis will be based on the evalu-
able-extension population. Sensitivity analyses will impute 
missing CT scan data for those not having endpoint CTs. 
The weighted average lumen diameter will be presented 
using descriptive statistics by type of solution (DuraGraft vs 
heparin-dosed saline) and time points (4–6 weeks and 12 
months). Changes from 4–6 weeks to 12 months will also 
be summarised by type of solution. This primary endpoint, 
change from 4–6 weeks to 12 months in the weighted 
average lumen diameter, will be compared between Dura-
Graft graft and heparin-dosed saline graft using a linear 
mixed model that will include terms for type of solution 
(DuraGraft vs heparin-dosed saline) and time points (4–6 
weeks and 12 months). A factor for target region (left and 
right) will also be included in the model. This model will 
account for the correlated nature of the grafts within the 
patients. The structure of the covariance matrix will be the 
one yielding the smallest AIC. Contrasts under this longi-
tudinal model will allow for the comparison of the change 
from 4–6 weeks to 12 months between the two solutions at 
the 0.05 significance level:
  
H0 : (µ12 months, SOMVC001 − µ4−6 weeks, SOMVC001)−
(µ12 months, heparin−dosed saline − µ4−6 weeks, heparin−dosed saline) = 0
[µdelta(SOMVC001−heparin−dosed saline) = 0]
vs.
H1 : (µ12 months, SOMVC001 − µ4−6 weeks, SOMVC001)−
(µ12 months, heparin−dosed saline − µ4−6 weeks, heparin−dosed saline) ̸= 0
[µdelta(SOMVC001−heparin−dosed saline) ̸= 0]   
where μ4–6 weeks, heparin-dosed saline, μ4–6 weeks, SOMVC001, μ12 months, hepa-
rin-dosed saline and μ12 months, SOMVC001 are, respectively, the mean of 
the weighted average lumen diameter in the heparin-dosed 
saline and DuraGraft solutions at 4–6 weeks and 12 months. 
In other words, this hypothesis will allow the comparison of 
the magnitude of the changes between 4–6 weeks and (3 
months) 12 months in the paired grafts. For the secondary 
endpoint analyses, a linear mixed model similar to the one 
for the primary endpoint will be used.
sample size calculation and assumptions
The sample size for this study is based on the literature 
since little actual information regarding the natural 
history of wall thickness following bypass has been 
published. Assuming the null hypothesis of no difference 
between the two paired grafts, then 90 individuals with 
randomised grafts to saline or DuraGraft will yield 80% 
power using a two-sided type I error of 0.05 against the 
hypothesis of superiority, assuming an effect size of at 
least 0.30 [(paired difference in mean wall thickness)/
SD of the difference]. That is, the DuraGraft preserved 
grafts will on average have lesser wall thickness than its 
paired heparin-dosed saline preserved grafts, and if the 
null hypothesis is rejected, then it may be concluded 
that DuraGraft preserves the graft better by virtue of the 
fact that it lessens the increase in wall thickness observed 
following bypass. To ensure a sufficient evaluable popula-
tion for this study, at least 100 patients should be enrolled 
to meet a targeted evaluable population of 90 patients 
(180 SVGs) and to account for any non-measurable grafts 
or dropouts, which may occur during the study period. If 
the missing data exceeds 5% or the result of Little’s test 
is significant (P<0.05), then multiple imputations will be 
used (SAS V.9.4 or higher).
safety analyses
Vein graft thrombosis (occlusion) as well as a composite 
safety endpoint will be assessed using McNemar’s test for 
paired observations displayed in the two-by-two table of 
the paired graft outcomes . Patency rate will be tested 
similarly, and descriptive data of the agreement and 
discordance rates will be presented.
trial organisation
The trial is carried out at seven investigational sites 
(Canada, Denmark and Ireland) and involves a total of 
28 different cardiothoracic surgeons. It has a steering 
committee and independent cardiac adverse event adju-
dications review committee.
trial status
Enrolment of 119 patients was successfully completed 
on 14 December 2016, and analysis MDCT angiography 
follow-up is ongoing with an expected completion by the 
end of 2017 with the completed analysis becoming avail-
able by end of the first quarter of 2018.
strength and implications of the trial
VGF still represents a major drawback in CABG impairing 
long-term clinical outcomes.3 Besides surgical trauma 
that may occur during  SVG harvest, in particular the 
suboptimal preservation of SVGs during storage (prior to 
anastomosis) has been demonstrated ex vivo to be a key 
trigger of endothelial damage, which may result in the 
development of VGD and ultimately failure.3
The present trial aims to establish whether the intraoper-
ative treatment of SVGs with DuraGraft has the potential to 
decrease and/or prevent the occurrence of VGD and VGF by 
reducing wall thickness increase and/or intima hyperplasia 
(as early signs of VGD) and the occurrence of SVG stenosis 
(lumen loss; late signs) in patients undergoing CABG 
surgery. In addition, it will further provide insight into the 
longitudinal behaviour of SVGs and the pathophysiology 
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Table 1 Study Protocol and short term follow up 
Study period
Schedule of events
Preoperative
screening
Intraoperative
CABG surgery Postoperative Follow-up*
Early discontinuation
visit
Study day\procedure −10 Days Day 1 Day 2
Days 3 to
discharge
Weeks
4–6
Month 3
(±1 week)
Obtain informed consent† X
Review inclusion and exclusion 
criteria
X
Medical history X
Demographics X
Prior medications X
Concomitant medications X X X X X X
12-lead ECG X X X
Randomisation‡ X
Operative study procedures X
ICU admission X
Measure chest tube blood loss X X
Cardiac assessments§
CKMB¶
X X
Troponin X
Glomerular filtration rate (GFR) X X X X
Vascular flow measurement** X
AEs X X X X X X
MDCT angiography X X X
*Follow-up at the weeks 4–6 and month 3 (+1 week) visit must be clinic visits.
†Inform consent must be obtained before any study-related procedures are conducted.
‡Randomisation will occur prior to saphenous vein is harvesting.
§Routine cardiac laboratory testing to be performed as per standard practice. CKMB, and troponin, laboratory results will be collected for the 
study patients. eGFR will be done.
¶CKMB testing at 8 hours (cay 1), 24 hours (day 2) and 48 hours (day 3) will be documented.
**Vascular conduit flow will be measured and recorded after reperfusion, prior to chest closure.
AE, adverse Events; CABG, coronary artery bypass grafting; CKMB, creatine kinase kinase myocardial bound; GFR, glomerular filtration rate; 
ICU, intensive care unit; MDCT, multidetector CT.
Table 2 Long term follow up 
Study period
6 (+1 month) 
post-CABG 
follow-up 
telephone-call
9 (+1 month) 
post-CABG 
follow-up 
telephone-call
12 (+1 month) post-CABG
follow-up
clinic visit
Early withdrawal/
discontinuation visit
clinic visit
Procedures/assessments
Concomitant medications 
(cardiovascular)
X X X X
Glomerular filtration rate 
(GFR)
X X
AEs X X X X
ECG X X
MDCT angiography X X
Note: informed consent must be obtained for patients who agree for an additional 9-month post-CABG surgery follow-up.
AE, adverse events; CABG, coronary artery bypass grafting;GFR, glomerular filtration r a t e; MDCT, multidetector CT.
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VGD and VGF. By longitudinal MDCT angiography, the 
magnitude of change in wall thickness (early signs) at 4–6 
weeks and at 3 months post-CABG and the magnitude of 
change of lumen diameter loss/development of stenosis 
(late signs) will be evaluated.
Indeed, MDCT angiography is a highly accurate tool to 
detect stenosis in bypass grafts with sensitivity, specificity, 
negative and positive predictive values of 97%, 97%, 93% 
and 99%, respectively.18 More specifically, 64-slice MDCT 
has been used to assess graft wall thickness and patency 
rates as early as 1 month and 12 months after CABG 
procedures.19 MDCT has demonstrated its sensitivity to 
measure wall thickness and lumen diameter. Lau and 
colleagues17 demonstrated MDCT measure of a non-oc-
cluded SVG mean loss of SVG lumen diameter of 9% 
(3.69–3.36 mm) between postoperative months 1 and 12. 
Therefore, the 64-slice or better MDCT angiography was 
selected for this study based on its general ability to assess 
vessel plaque volume and percentage diameter stenosis 
with excellent sensitivity and specificity,20 including the 
assessment of SVG wall thickness.
According to Lau et al, intimal hyperplasia as assessed 
by wall thickening occurs and can be measured within 4–6 
weeks post-CABG. This timing is consistent with mecha-
nisms elucidated in animal models of intimal hyperplasia. 
Furthermore, clinical wall thickening can stabilise or regress 
sometime between 1 month and 12 months post-CABG.17 
Interestingly, clinical data on SVGs used for peripheral 
bypass surgery indicate that wall thickening stabilises at 3 
months and begins to regress at 6 months postgrafting.21 
While indeed wall thickness measurements have been 
established as meaningful measurements for assessing 
the risk for development of cardiac events and mortality, 
the amount of wall thickness or magnitude of change in 
wall thickness that translates into a clinically meaningful 
prognostic value remains unclear. In part, this is due to 
differences in measurement procedures, limited studies 
assessing early (<6 months post-CABG) wall changes, and 
the error in measurement within a specific imaging meth-
odologies such as MDCT, optical coherence tomography 
(OCT), Intravascular Ultrasound (IVUS) or others.
Finally, the sophisticated within-patient design used in 
this trial (with each patient having two graft segments 
with one immersed in DuraGraft and the other in 
heparin dosed saline) will facilitate a paired analysis of 
SVGs within each patient. Importantly, this will allow for 
a better control of other factors contributing to VGD and 
VGF within a patient and thus will substantially reduce 
a potential outcome bias due to patient-specific or 
conduit-specific variabilities.
Ethics and dissemination
All patients provided written informed consent before 
enrolment into the trial. Results will be submitted for 
publication in a peer-reviewed journal.
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